Current standards in the treatment of chronic hepatitis C;Behandlung von Patienten mit chronischer Hepatitis C

Deutsches Arzteblatt International

Volumn 109, Issue 19, 2012, Pages 352-358

  Hofmann, Wolf Peter ^a   Sarrazin, Christoph ^a   Zeuzem, Stefan ^a  

^a UNIVERSITY HOSPITAL FRANKFURT   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

BOCEPREVIR; PEGINTERFERON ALPHA; RIBAVIRIN; TELAPREVIR;

GENOTYPE; HEPATITIS C; HUMAN; RELAPSE; REVIEW; TREATMENT DURATION; TREATMENT OUTCOME; UNSPECIFIED SIDE EFFECT;

EID: 84903362148     PISSN: 18660452     EISSN: None     Source Type: Journal    
DOI: 10.3238/arztebl.2012.0352     Document Type: Review

References (25)

1. Sarrazin C, Berg T, Ross RS, et al.: [Prophylaxis, diagnosis and therapy of hepatitis C virus (HCV) infection: the German guidelines on the management of HCV infection]. Z Gastroenterol 2010; 48: 289-351.
2. Seeff LB. Natural history of chronic hepatitis C. Hepatology 2002; 36: 35-46.
3. Fattovich G, Stroffolini T, Zagni I, Donato F: Hepatocellular carcinoma in cirrhosis: incidence and risk factors. Gastroenterology 2004; 127: 35-50.
4. Manns MP, McHutchison JG, Gordon SC, et al.: Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet 2001; 358: 958-65.
5. Zeuzem S, Hultcrantz R, Bourliere M, et al.: Peginterferon alfa-2b plus ribavirin for treatment of chronic hepatitis C in previously untreated patients infected with HCV genotypes 2 or 3. J Hepatol 2004; 40: 993-9.
6. Fried MW, Shiffman ML, Reddy KR, et al.: Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med 2002; 347: 975-82.
7. EASL Clinical Practice Guidelines: management of hepatitis C virus infection. J Hepatol 2011; 55: 245-64.
8. Simmonds P, Bukh J, Combet C, et al.: Consensus proposals for a unified system of nomenclature of hepatitis C virus genotypes. Hepatology 2005; 42: 962-73.
9. Kau A, Vermehren J, Sarrazin C: Treatment predictors of a sustained virologic response in hepatitis B and C. Journal of Hepatology 2008; 49: 634-51.
10. Clark PJ, Thompson AJ, McHutchison JG: IL28B Genomic-Based Treatment Paradigms for Patients With Chronic Hepatitis C Infec - tion: The Future of Personalized HCV Therapies. Am J Gastroenterol 2011; 106: 38-45.
11. Veldt BJ, Heathcote EJ, Wedemeyer H, et al:. Sustained virologic response and clinical outcomes in patients with chronic hepatitis C and advanced fibrosis. Ann Intern Med 2007; 147: 677-84.
12. Poynard T, Colombo M, Bruix J, et al.: Peginterferon alfa-2b and ribavirin: effective in patients with hepatitis C who failed interferon alfa/ribavirin therapy. Gastroenterology 2009; 136: 1618-28.e1612.
13. Jensen DM, Marcellin P, Freilich B, et al.: Re-treatment of patients with chronic hepatitis C who do not respond to peginterferonalpha2b: a randomized trial. Ann Intern Med 2009; 150: 528-40.
14. Soriano V, Vispo E, Poveda E, et al.: Directly acting antivirals against hepatitis C virus. J Antimicrob Chemother 2011; 66: 1673-86.
15. Sarrazin C, Berg T, Cornberg M, et al.: [Expert opinion on boceprevir- and telaprevir-based triple therapies of chronic hepatitis C]. Z Gastroenterol 2012; 50: 57-72.
16. Hofmann WP, Zeuzem S: A new standard of care for the treatment of chronic HCV infection. Nat Rev Gastroenterol Hepatol 2011; 8: 257-64.
17. Poordad F, McCone J, Bacon B, et al.: Boceprevir for untreated chronic HCV genotype 1 infection. N Engl J Med 2011; 364: 1195-206.
18. Kwo PY, Lawitz EJ, McCone J, et al.: Efficacy of boceprevir, an NS3 protease inhibitor, in combination with peginterferon alfa-2b and ribavirin in treatment-naive patients with genotype 1 hepatitis C infection (SPRINT-1): an open-label, randomised, multicentre phase 2 trial. Lancet 2010; 376: 705-16.
19. Jacobson IM, McHutchison JG, Dusheiko G, et al.: Telaprevir for previously untreated chronic hepatitis C virus infection. N Engl J Med 2011; 364: 2405-16.
20. Sherman KE, Flamm SL, Afdhal NH, et al.: Response-guided telaprevir combination treatment for hepatitis C virus infection. N Engl J Med 2011; 365: 1014-24.
21. Bacon B, Gordon SC, Lawitz E, et al.: HCV RESPOND-2 Investigators. Boceprevir for previously treated chronic HCV genotype 1 infection. N Engl J Med 2011; 364: 1207-17.
22. Zeuzem S, Andreone P, Pol S, et al.: Telaprevir for retreatment of HCV infection. N Engl J Med 2011; 364: 2417-28.
23. Sarrazin C, Zeuzem S. Resistance to Direct Antiviral Agents in Patients with Hepatitis C Virus Infection. Gastroenterology 2010; 138: 447-62.
24. Boceprevir-Nutzenbewertung des Instituts für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) gemäβ 35a SGB V (Dossierbewertung). Stellungnahme des Vorstands der Deutschen Gesellschaft für Verdauungs- und Stoffwechselkrankheiten (DGVS). Z Gastroenterol 2012; 50: 20-1.
25. Telaprevir-Nutzenbewertung des Instituts für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) gemäβ 35a SGB V (Dossierbewertung). Stellungnahme des Vorstands der Deutschen Gesellschaft für Verdauungs- und Stoffwechselkrankheiten (DGVS). Z Gastroenterol 2012; 50: 271-2.